Fcer1g-flox Mouse
一般名
Fcer1g-flox
製品ID
S-CKO-02376
背景情報
C57BL/6JCya
系統ID
CKOCMP-14127-Fcer1g-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Fcer1g-flox Mouse(カタログ番号S-CKO-02376)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Fcer1g-flox
系統ID
CKOCMP-14127-Fcer1g-B6J-VA
遺伝子名
製品ID
S-CKO-02376
遺伝子別名
CD23, Fce1g, Ly-50, FcR[g], FcRgamma, FcR-gamma, FcepsilonRI
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 1
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000079957
NCBIトランスクリプトID
NM_010185
ターゲット領域
Exon 2~5
有効領域の大きさ
~2.5 kb
遺伝子研究の概要
Fc Fragment of IgE Receptor Ig (FCER1G), also known as the high-affinity IgE receptor gamma subunit gene, plays a pivotal role in allergic inflammatory signaling, closely associated with allergic reactions. It is an innate immunity gene involved in many immune-related pathways encompassing multiple cell types [3].
FCER1G has been studied in various disease contexts. In cardioembolic stroke (CE), it could serve as a novel potential blood biomarker, helping distinguish CE from non-cardioembolic stroke. The development of a nomogram using FCER1G and other CE-associated risk factors showed high precision in risk delineation [1].
In rheumatoid arthritis (RA), patients have lower levels of FCER1G gene methylation compared to controls, suggesting it may be a new potential epigenetic marker of RA independent of disease activity [2].
In pan-cancer studies, FCER1G can act as a prognostic marker, with its expression affecting patients' prognosis and correlating with immune cells infiltration. For example, in kidney renal clear cell carcinoma, high expression of FCER1G is related to tumor-associated macrophage infiltration and T-cell suppression, contributing to an unfavorable prognosis [3,4].
In multiple myeloma, the expression level of FCER1G negatively correlates with myeloma progression, and high FCER1G expression may be a favorable biomarker [5].
In female patients with Vogt-Koyanagi-Harada disease, downregulation of FCER1G due to DNA hypermethylation is responsible for resistance to the combination of cyclosporin A and corticosteroids, and chlorambucil reverses this resistance by inducing FCER1G expression via DNA demethylation [6].
In conclusion, FCER1G is crucial in immune-related biological processes and shows potential as a biomarker and a target in various diseases such as stroke, autoimmune diseases, and cancers. Studies on FCER1G contribute to a better understanding of disease mechanisms and may offer new strategies for diagnosis and treatment.
References:
1. Hu, Yuanzheng, Li, Xiangxin, Hou, Kaiqi, Bai, Fanghui, Xu, Qian. 2024. FCER1G as a novel immune-associated blood biomarker in cardiogenic stroke. In Heliyon, 10, e33846. doi:10.1016/j.heliyon.2024.e33846. https://pubmed.ncbi.nlm.nih.gov/39071704/
2. Podgórska, Dominika, Cieśla, Marek, Kolarz, Bogdan. 2022. FCER1G Gene Hypomethylation in Patients with Rheumatoid Arthritis. In Journal of clinical medicine, 11, . doi:10.3390/jcm11164664. https://pubmed.ncbi.nlm.nih.gov/36012903/
3. Zhang, Xiaoxuan, Cai, Jing, Song, Fangzhou, Yang, Zhenzhou. 2022. Prognostic and immunological role of FCER1G in pan-cancer. In Pathology, research and practice, 240, 154174. doi:10.1016/j.prp.2022.154174. https://pubmed.ncbi.nlm.nih.gov/36332324/
4. Dong, Keqin, Chen, Wenjin, Pan, Xiuwu, Yang, Fu, Cui, Xingang. 2022. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity. In BMC cancer, 22, 140. doi:10.1186/s12885-022-09251-7. https://pubmed.ncbi.nlm.nih.gov/35120484/
5. Fu, Lin, Cheng, Zhiheng, Dong, Fen, Chen, Yang, Si, Chaozeng. 2020. Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. In Journal of Cancer, 11, 1182-1194. doi:10.7150/jca.37313. https://pubmed.ncbi.nlm.nih.gov/31956364/
6. Chang, Rui, Ji, Yan, Xu, Jing, Su, Guannan, Yang, Peizeng. 2023. Identification of FCER1G as a cyclosporin A plus corticosteroid sensitization gene in female patients with Vogt-Koyanagi-Harada disease. In Clinical immunology (Orlando, Fla.), 256, 109800. doi:10.1016/j.clim.2023.109800. https://pubmed.ncbi.nlm.nih.gov/37821074/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
